ATE335832T1 - Für gdnf-kodierende rekombinante adenoviren - Google Patents

Für gdnf-kodierende rekombinante adenoviren

Info

Publication number
ATE335832T1
ATE335832T1 AT95914402T AT95914402T ATE335832T1 AT E335832 T1 ATE335832 T1 AT E335832T1 AT 95914402 T AT95914402 T AT 95914402T AT 95914402 T AT95914402 T AT 95914402T AT E335832 T1 ATE335832 T1 AT E335832T1
Authority
AT
Austria
Prior art keywords
gdnf
adenovirus
recombinant adenoviruses
cell
dna sequence
Prior art date
Application number
AT95914402T
Other languages
English (en)
Inventor
Philippe Horellou
Jacques Mallet
Michel Perricaudet
Frederic Revah
Emmanuelle Vigne
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE335832T1 publication Critical patent/ATE335832T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95914402T 1994-03-25 1995-03-23 Für gdnf-kodierende rekombinante adenoviren ATE335832T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403542A FR2717824B1 (fr) 1994-03-25 1994-03-25 Virus recombinants, préparation et utilisation en thérapie génique.

Publications (1)

Publication Number Publication Date
ATE335832T1 true ATE335832T1 (de) 2006-09-15

Family

ID=9461438

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914402T ATE335832T1 (de) 1994-03-25 1995-03-23 Für gdnf-kodierende rekombinante adenoviren

Country Status (14)

Country Link
US (1) US6245330B1 (de)
EP (1) EP0752004B1 (de)
JP (1) JPH09510620A (de)
KR (1) KR100403707B1 (de)
AT (1) ATE335832T1 (de)
AU (1) AU704910B2 (de)
CA (1) CA2184841C (de)
DE (1) DE69535155T2 (de)
FI (1) FI963805L (de)
FR (1) FR2717824B1 (de)
IL (1) IL113109A0 (de)
MX (1) MX9604024A (de)
WO (1) WO1995026408A1 (de)
ZA (1) ZA952433B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE404683T1 (de) * 1992-09-25 2008-08-15 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
US20020031493A1 (en) * 1994-03-25 2002-03-14 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
AU6975198A (en) * 1997-04-15 1998-11-11 University Of Medicine And Dentistry Of New Jersey Cdna for human gdnf and promoter therefor which allows regulated and constitutive expression
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
IL146694A (en) 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
IL162630A0 (en) 2001-12-21 2005-11-20 Salk Inst For Biological Studi A composition containing a viral vector containinga heterologous gene to be transduced into a neuron
AU2004304716B2 (en) * 2003-12-18 2010-05-27 Biomas Ltd. Tellurium derivatives for prevention and treatment of neurodegenerative processes
DK2019683T4 (da) 2006-04-25 2022-08-29 Univ California Indgivelse af vækstfaktorer til behandling af CNS-lidelser
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
JP2010531638A (ja) 2007-06-12 2010-09-30 ケース ウエスタン リザーブ ユニバーシティ 標的化された細胞死
WO2010011404A2 (en) 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
WO2013007874A1 (en) 2011-07-12 2013-01-17 Mart Saarma A transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene.
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
LT3727234T (lt) 2017-12-22 2022-04-25 Coloplast A/S Ostomijos prietaisas su kampinio nuotekio aptikimu
EP3764961B1 (de) 2018-03-15 2024-02-21 Coloplast A/S Vorrichtung und verfahren zum navigieren des benutzers einer stomavorrichtung zu einem umkleideraum

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
ATE404683T1 (de) * 1992-09-25 2008-08-15 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
MX9604024A (es) 1997-09-30
AU704910B2 (en) 1999-05-06
FR2717824B1 (fr) 1996-04-26
FI963805A7 (fi) 1996-09-24
AU2141195A (en) 1995-10-17
DE69535155D1 (de) 2006-09-21
FI963805A0 (fi) 1996-09-24
JPH09510620A (ja) 1997-10-28
FI963805L (fi) 1996-09-24
IL113109A0 (en) 1995-06-29
KR100403707B1 (ko) 2004-02-11
ZA952433B (en) 1996-01-15
CA2184841C (fr) 2009-08-18
DE69535155T2 (de) 2007-06-28
KR970702373A (ko) 1997-05-13
EP0752004A1 (de) 1997-01-08
EP0752004B1 (de) 2006-08-09
US6245330B1 (en) 2001-06-12
CA2184841A1 (fr) 1995-10-05
FR2717824A1 (fr) 1995-09-29
WO1995026408A1 (fr) 1995-10-05

Similar Documents

Publication Publication Date Title
ATE335832T1 (de) Für gdnf-kodierende rekombinante adenoviren
Leslie et al. Nerve growth factor contributes to the up-regulation of growth-associated protein 43 and preprotachykinin A messenger RNAs in primary sensory neurons following peripheral inflammation
Cantini et al. Macrophages regulate proliferation and differentiation of satellite cells
Cucchiarini et al. Restoration of the extracellular matrix in human osteoarthritic articular cartilage by overexpression of the transcription factor SOX9
Akimoto et al. Adenovirally expressed basic fibroblast growth factor rescues photoreceptor cells in RCS rats.
Korte et al. Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice.
Di Polo et al. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Müller cells temporarily rescues injured retinal ganglion cells
Kan et al. Hepatocyte growth factor/hepatopoietin A stimulates the growth of rat kidney proximal tubule epithelial cells (RPTE), rat nonparenchymal liver cells, human melanoma cells, mouse keratinocytes and stimulates anchorage-independent growth of SV-40 transformed RPTE
Chandler et al. Matrix‐enabled gene transfer for cutaneous wound repair
Barkats et al. Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases
MATSUMOTO et al. Hepatocyte growth factor: molecular structure and implications for a central role in liver regeneration
Popko et al. Nerve regeneration occurs in the absence of apolipoprotein E in mice
JP2005512515A5 (de)
DE69940899D1 (de) AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung
BR9710689A (pt) Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia
JP2007525990A (ja) 脊髄状態の治療
DE69930622D1 (de) Behandlung von osteoporose
Sekiguchi et al. Human tissue fibronectin: expression of different isotypes in the adult and fetal tissues
Robert et al. Adenovirus-mediated transfer of a functional GAD gene into nerve cells: potential for the treatment of neurological diseases
Savona et al. Proteoheparan sulfates contribute to the binding of basic FGF to its high affinity receptors on bovine adrenocortical cells
WO1994017831A9 (en) A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
Fang et al. Human placenta‐derived mesenchymal stem cell administration protects against acute lung injury in a mouse model
Vestri et al. Duplication of the hemoglobin α-chain gene in sheep: characterization of a new α-chain variant present in animals possessing the αLeu and theIIαHis chains
Horellou et al. In VivoAdenovirus-Mediated Gene Transfer for Parkinson's Disease
Welcher et al. Molecular approaches to nerve regeneration

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties